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Under the clinical queries is another option called “My NCBI”, for
which you need to register and provide a password and ID (which
is free). This is a very useful option as it allows you to save your
searches, and then access them at another time. My NCBI will
also automatically update your search as newer studies are added
to the database and can even e-mail you to tell you that the
search has been updated. This is especially thrilling when you
have published your research, and NCBI emails you your own
article!
Where to Learn More
PubMed has an online tutorial on how to search MEDLINE, which
is very useful.3 There are also other published articles4 and books
on how to get the most of your medline search. NCBI have
uploaded tutorials on YouTube on how to use search Medline
(http://www.youtube.com/user/NCBINLM)….things have come a
long way since looking up Index Medicus in the library on a wet
Wednesday night in November!
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What is the difference between a cohort and a case-control trial?
And why is it important? As a student, it is sometimes difficult to
appreciate the difference between these two study methods, and
why should it matter to us anyway? After all, we study medicine to
treat patients, not statistics. Study methodologies were for the
scientists; we are clinicians. Fast forward to clinical practice, and
the importance of research design becomes apparent. As medical
doctors we treat patients, but we also look at the bigger picture:
why is this happening to this patient? Why is this patient more
likely to be affected than another? In order to truly care for
patients it is necessary to search and query and that means doing,
or being able to properly interpret, research.
The most fundamental point of both cohort and case-control trials
is that they are observational trials. Unlike randomised controlled
trials (RCTs), where the researchers actively divide participants
into control and comparison groups, observational trials are more
passive: here the researchers literally observe participants. The
major drawback is the potential for bias: apparent differences may
be due to known or unknown confounders.1 However, in emotive
or ethically difficult areas (e.g., obstetrics or paediatrics) or in
situations when blinded randomisation is not possible (e.g.,
surgical procedures) they may be the best quality evidence
available.
To illustrate the differences between the two study types, a good
example is the history of research into lung cancer. We all know
that smokers are more likely to develop lung cancer, but where did
that knowledge come from? And what if you look at this from the
other direction: “How many persons with lung cancer were
smokers?” These two ways of looking at a question illustrate the
differences between a cohort and a case-control trial perfectly. In
fact, over fifty years ago in the UK a young doctor and a
statistician asked just that same question and decided to use
these two methods to find an answer.
Case-Control
How many people with lung cancer were smokers?
Sir Richard Doll (an epidemiologist) and Sir Austin Bradford Hill (a
statistician) started off by looking at patients with lung cancer: the
“cases”. They then picked a group of controls, patients without
lung cancer but in hospital for another reason. Looking back in
time (retrospectively) they tried to ascertain what the cases had
been exposed to that made them more likely to develop lung
cancer than the controls.2 The cases were divided into those
exposed to smoking and those unexposed. A similar group (in this
case, other hospital patients) were similarly divided into exposed
and unexposed groups (Figure 1). Due to the risk of confounding
(see below) the researcher then assumes (and hopes!) that the
cases and controls come from the same population.3 So the key
features to a case-control trial are retrospective and comparison.4
Figure 1 Case Control Trial
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The difficulty can, sometimes, be deciding who has been exposed
or unexposed: smoking might be obvious, but what do you do with
ex-smokers? And what if the exposure is not obvious: how many
mothers, for example, would know if they took certain medications
during pregnancy? While those who have the disease may have
searched for a cause, those without the disease may never be
aware of the exposure they had. This can lead to “recall bias” as
participants may deny having been exposed, simply because the
exposure meant nothing to them.4
A second difficulty is choosing your controls: what if Doll and Hill
had chosen patients with emphysema? Their smoking outcome
(lung cancer versus emphysema) would have been different but
their smoking habits might have been the same. These are called
confounders: factors which link two groups and suggest a causal
relationship. While some confounders are obvious (e.g., grey
haired people have higher surgical mortality) others are not so
obvious (e.g., eating eggs increases your risk of a myocardial
infarction, or is this confounded by regularly eating fried bacon
with these eggs?). This is another advantage of RCTs over
observational trials: RCTs balance groups for confounders that
have not yet been described.3
Case-control trials are usually retrospective, so the data are
usually ready to be collected; therefore the study is cheaper and
quicker to complete than a prospective trial. This is an advantage
when studying diseases with a long latency period. Equally, if you
are researching a rare disease or outcome using a cohort study, it
would require huge numbers of exposed persons and many years
to obtain enough people who develop the rare outcome.
Therefore, a case-control trial (where the participants have already
developed the rare outcome) is a more efficient use of resources
and would require a smaller sample size5. However, the
information available is limited by what other people thought was
important at the time the data were recorded and this, in itself,
may lead to bias.
The key featuress to case-control trials, therefore, are outcome,
(usually) retrospective, rare outcome or long latency period. It is,
however, also possible to have prospective case-control trials:
take for example a study of serum lipoprotein as a risk factor for
coronary heart disease. Here, the participants (men aged 50
years) had blood samples taken and frozen. Fast forward six
years, through which the men were followed to see whether they
had developed coronary heart disease or not. Those who had (the
cases) were compared to randomly selected controls from the
remaining participants. The blood samples of the two groups were
compared to see if they differed with respect to their
concentration of serum lipoprotein(a). This meant that not all the
blood samples needed to be analysed, but that the cases could be
accurately compared to controls for exposure to differing
concentrations of lipoprotein(a) (this is an example of a nested
case-control trial, that is, a case-control trial nested within a
cohort trial5).
The main disadvantage of prospective case-control trials is that
the ratio of cases to controls is artificially ‘created’, meaning that
the prevalence of the condition cannot be estimated from the data
collected and so absolute risks and, therefore, relative risks
cannot be estimated either. Therefore, odds ratios are given for
any risk factors.
Cohort
Smokers are more likely to develop lung cancer
The key features to a cohort trial is to follow a group of exposed
persons forward in time to see if they develop the outcome.6 For
example, if people are followed prospectively to evaluate if
smokers are more likely to develop cancer than non-smokers.
(There are also retrospective cohort trials but for the moment, the
key features to a cohort trial are exposure and prospective. Thus a
cohort trial is also termed a prospective trial). In epidemiology, a
cohort is a defined population that is followed prospectively to see
who develops an illness. No new additions are made, and an
attempt is made to follow all those who comprised the original
group.7
In Doll and Hill’s study where the outcome was lung cancer, the
study would require years of follow up to see if any of the
participants would ever develop the disease. (There’s no point in
stopping follow up at twenty years if patients may be diagnosed
after twenty-five years). Due to the time and effort required, it is
first important to at least have a basis for your hypothesis: this is
why many researchers start with a case-control trial (as Doll and
Hill did). Another disadvantage of the time required for the study
is the loss to follow up: how do you keep in contact with your
original study group? Doll and Hill very sensibly decided to have
as their cohort doctors registered with the General Medical
Council (the GMC, the professional organisation for medical
doctors in the UK). So they would have a group of participants
who would be easier to follow (as they needed to remain
registered with the GMC) and would also, appreciate the
importance of participation in such a study.
The cohort trial of British medical doctors has been published
every five years since 19549, the last update being published in
2004.10 The original trial gained worldwide notice, and resulted in
similar trials starting in other countries, including the Nurses
Health study in the US.11. Information obtained on multiple
outcomes in smokers was obtained which has significantly
changed medical treatment. However, this is a very long-term
study and involved significant work from the authors and their
support teams.
The advantage of cohort studies over case-control studies is that
as long as a representative cohort has been recruited, then
prevalence, absolute and relative risks can be estimated readily
for any risk factors.
In summary, case-control trials and cohort trials are easily
confused, so the key features are shown in Table 1. Both are
observational trials. However, case-control trials compare cases
with controls to investigate what each group was exposed to such
that cases become cases and the controls remain controls. So,
the key features to case-control trials are retrospective (usually)
and outcome. In contrast, cohort trials only investigate one group
and usually follow them forward in time to see if they develop a
disease. Therefore, the key features to cohort trials are exposure
and prospective (usually).
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The basics
A randomised controlled trial (RCT), also known as a randomised
controlled clinical trial, is a study in which participants are
assigned randomly to one of two or more arms (groups with
different interventions) of a clinical trial. Occasionally, a placebo is
used as one of the interventions, but, generally, if there is a
recognised and accepted intervention that works (the “gold
standard”), then a new drug, device or intervention is tested
against this gold standard rather than against placebo. Where a
gold standard drug or intervention exists, it would be unethical to
randomise to a placebo and, by doing so, make an effective
treatment unavailable to some participants. Generally, RCTs are
conducted because there is equipoise (or uncertainty) about
whether a new intervention is potentially better than an existing
one. The trialists (the team of people that plan, conduct, supervise
and analyse the results of the trial) start with the hypothesis that
there is no difference between the two interventions (this is “the
null hypothesis”). The purpose of the RCT is to reject or accept
the null hypothesis. If they manage to reject the null hypothesis,
they can accept the “alternative hypothesis”, i.e., that there is a
difference between the two interventions.
Blinding
RCTs can be, but are not always, blinded. Blinding means that
someone who plays an active part in the trial does not know what
treatment (new intervention, gold standard or placebo) has been
assigned to each participant. Trials can be single-blinded, double-
blinded or even triple-blinded depending on how many types of
people involved in the trial are blinded. For example, the
participant could be blinded and not know what intervention they
are assigned to. Or the medical doctor who deals with all the
participants might not know to which intervention each participant
is assigned. Or the statistician who reviews all the datasets and
performs the statistical analysis might not know which group of
participants has been assigned to which intervention. As you can
imagine, if the participants are blinded, then there is less
likelihood that they will complain of symptoms or side-effects that
are known to be associated with either the new intervention, or
the gold standard, or placebo. Similarly, a blinded doctor is less
likely to assess patients in a biased way. To avoid the bias the
statistical tests should be chosen prior to starting the RCT along
with the rationale given for choosing them). Everybody has biases
– even you!
Random Allocation
RCTs by definition, randomly allocate participants to the different
arms. This is designed to mimic chance, and to ensure that there
is no difference between groups. A good trial published in a
journal will show the characteristics of the various intervention
groups summarised (usually in a table) and compared (often with
p values and confidence intervals, though not always) to prove to
the reader that there are no differences at baseline.
Randomisation does not mean assigning alternate treatments to
every second patient, nor assigning intervention A to patients who
present on Mondays, Wednesdays and Fridays and intervention B
to all others; if a well-meaning, but biased, physician wants his
favourite patient to be assigned to intervention A he can tell that
patient to come in on the day that intervention will be assigned;
this is known as selection bias. Randomisation is designed to
prevent biases, as well as to ensure “same-ness” between the
assignment groups. The best method of randomisation is to use
computer software to generate a sequence of random numbers,
where each number refers to one of the interventions.
Sample Size Calculations
Calculating the number of patients needed for a trial is important.1
If you can show that a new intervention is statistically significantly
better than the old intervention by randomising fifty patients, you
can avoid the expense of randomising and treating one hundred
patients (which would also be unethical if the new treatment was
beneficial). On the other hand twenty-five patients might not be
enough to detect a statistically significant difference, even if a
difference truly does exist (this is a type II error). In other words
the ‘power’ of the study was too low to show the difference. To
avoid costly errors when planning a trial, trialists use a nomogram
(e.g., Altman’s nomogram2) inputting three pieces of information:
the required level of statistically significant difference (usually to
0.05 or 0.01 level); a pre-determined difference between the
interventions that would be clinically relevant; and the power of
the study (the risk of making a type 2 error), which the trialists
choose to set at a pre-determined level (often around 80%). This
nomogram then calculates how many patients are needed to
show this predetermined clinical difference, at the predetermined
power and level of statistical significance. This is the total number
of participants needed to complete the trial. Most trialists will try
to recruit more than this, to allow for drop-outs during the study
period. Sample sizing software can also be used to calculate the
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